Institutional Manager · CIK 0001560009
Versant Venture Management, LLC
SAN FRANCISCO, CA · File #028-16849
Latest AUM
$151.1M
Positions
7
Top-10 Concentration
100.0%
Filings
9
Portfolio Value Over Time
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
Biggest QoQ Changes
Ranked by conviction flow (share change × current price) so mark-to-market moves don't dominate. Price effect column shows how much of the $ change was just the stock moving.
| Action | Issuer | Ticker / CUSIP | Δ Shares | Flow ($) | Price Effect |
|---|---|---|---|---|---|
| REDUCE | Monte Rosa Therapeutics, Inc. | GLUE | -1,270,235 | -$19.9M | +$46.7M |
| EXITED | Repare Therapeutics, Inc. | 760273102 | -2,646,657 | -$4.7M | $0 |
| EXITED | Adverum Biotechnologies, Inc. | 00773U108 | -506,821 | -$2.3M | $0 |
| REDUCE | Contineum Therapeutics, Inc. | CTNM | 0 | $0 | -$173,641 |
| REDUCE | CRISPR Therapeutics AG | CRSP | 0 | $0 | -$1.8M |
| REDUCE | Jade Biosciences, Inc. | JBIO | 0 | $0 | +$10.4M |
| REDUCE | Lenz Therapeutics, Inc. | LENZ | 0 | $0 | -$81.2M |
| REDUCE | Skye Bioscience, Inc. | SKYE | 0 | $0 | -$6.4M |
| REDUCE | Tempest Therapeutics, Inc. | TPST | 0 | $0 | -$2.0M |
Sector Allocation
Filing History
- 13F HOLDINGS REPORTQ/E Dec 20257 pos · $151.1M
- 13F HOLDINGS REPORTQ/E Sep 20259 pos · $212.5M
- 13F HOLDINGS REPORTQ/E Jun 20258 pos · $82.1M
- 13F HOLDINGS REPORTQ/E Mar 20257 pos · $60.2M
- 13F HOLDINGS REPORTQ/E Dec 20247 pos · $86.7M
- 13F HOLDINGS REPORTQ/E Sep 20246 pos · $63.6M
- 13F HOLDINGS REPORTQ/E Jun 20248 pos · $77.3M
- 13F HOLDINGS REPORTQ/E Mar 20247 pos · $103.1M
- 13F HOLDINGS REPORTQ/E Dec 20238 pos · $188.1M
Top 7 Holdings — Dec 2025
| # | Issuer | Ticker | Shares | Value | % of Portfolio |
|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc. | GLUE | 4,382,687 | $68.7M | 45.49% |
| 2 | Lenz Therapeutics, Inc. | LENZ | 2,656,888 | $42.5M | 28.14% |
| 3 | Jade Biosciences, Inc. | JBIO | 1,525,820 | $23.5M | 15.59% |
| 4 | CRISPR Therapeutics AG | CRSP | 148,831 | $7.8M | 5.17% |
| 5 | Contineum Therapeutics, Inc. | CTNM | 542,628 | $6.2M | 4.11% |
| 6 | Skye Bioscience, Inc. | SKYE | 2,007,704 | $1.5M | 1.00% |
| 7 | Tempest Therapeutics, Inc. | TPST | 269,772 | $774,246 | 0.51% |